National Cancer Institute

Funding Opportunities

Sponsor Title Deadline Deadline 2 Deadline 3 FOA
National Cancer Institute (NCI) Notice of Special Interest (NOSI): Understanding the effects of cancer and cancer treatment on aging trajectories and aging outcomes 1/8/24 –– –– NOT-CA-21-031
National Cancer Institute (NCI) Notice of Special Interest (NOSI): Expanding Cancer Control Research in Persistent Poverty Areas 9/25/21 1/7/22 1/25/22 NOT-CA-21-071
National Cancer Institute (NCI) Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer (R01 Clinical Trial Not Allowed) 11/8/21 –– PAR-19-198
National Cancer Institute (NCI) Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer (R21 Clinical Trial Not Allowed) 11/8/21 –– PAR-19-199
National Cancer Institute (NCI) Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention (R01 Clinical Trial Optional) 7/8/21 11/8/21 –– PAR-19-251
National Cancer Institute (NCI) Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Aggressive Cancer (R01 Clinical Trial Optional) 7/9/21 12/10/21 –– PAR-19-264
National Cancer Institute (NCI) Exploratory Grants in Cancer Epidemiology (R21 Clinical Trial Optional) 10/8/21 –– PAR-19-277
National Cancer Institute (NCI) Research Projects in Cancer Systems Biology (U01 Clinical Trial Optional) 7/9/21 11/15/21 –– PAR-19-287
National Cancer Institute (NCI) Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) 9/20/21 2/11/22 –– PAR-19-325
National Cancer Institute (NCI) Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R21 Clinical Trial Optional) 10/13/21 6/5/22 PAR-19-339